Long-Term Treatment Adherence and Persistence in Hypercortisolism

In this episode, ‘Long-Term Treatment Adherence and Persistence in Hypercortisolism,’ the panelists explore the factors that influence long-term treatment success and the challenges of maintaining adherence to medical therapy in patients with hypercortisolism. The expert faculty emphasize that effective management extends beyond medication selection and requires patient education, clear expectations, ongoing monitoring, and coordinated multidisciplinary care.

The panel examines how individualized treatment strategies can support long-term persistence by aligning therapy choices with patient comorbidities, treatment goals, and tolerability. They discuss the importance of helping patients understand the chronic nature of hypercortisolism and preparing them for the realities of long-term disease management.

The conversation also addresses common barriers to adherence, including adverse effects, complex monitoring requirements, healthcare access limitations, and the burden of frequent testing and follow-up. The panelists highlight how treatment-related glucocorticoid withdrawal symptoms and overly aggressive dose escalation may contribute to early discontinuation, underscoring the need for careful titration and close clinical follow-up.

Finally, the faculty review real-world adherence patterns and discuss disease-specific challenges, such as cyclic disease activity, persistent comorbidities, and ongoing cortisol dysregulation. Through practical insights and clinical experience, the panel reinforces the value of a patient-centered, team-based approach to improving long-term outcomes and sustaining engagement throughout the treatment journey.

The next episode in this series, ‘Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism,’ features the panelists discussing how clinicians balance sustained cortisol control with long-term metabolic risk management. The expert faculty also explore monitoring strategies, treatment individualization, and the importance of assessing both biochemical control and clinical outcomes over time.